Rivoglitazone

 Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.[1][2]

Rivoglitazone
Rivoglitazone.svg
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • (RS)-5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl) methoxy]benzyl}-1,3-thiazolidine-2,4-dione
CAS Number
  • 185428-18-6
PubChem CID
  • 3055168
ChemSpider
  • 2316729
UNII
  • 3A3N0634Q6
ChEMBL
  • ChEMBL2104753
Chemical and physical data
FormulaC20H19N3O4S
Molar mass397.45 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
InChI
  • InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25)
  • Key:XMSXOLDPMGMWTH-UHFFFAOYSA-N
  (verify)

It is being developed by Daiichi Sankyo.

This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License.